Payment overview · 2025
General Payments
$3,836.54
186 reported records · 29 companies
Healthcare provider profile · identity verified
Andrew Egan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSBURGH, PA · NPI 1134652878
Verified facts
What the public records show
CMS Open Payments records show Andrew Egan, MD received $3,836.54 in general payments during 2025 across 186 reported records.
Novo Nordisk Inc accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rexulti, Shingrix, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $555.59 | 14.5% | 28 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $533.66 | 13.9% | 27 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $297.64 | 7.8% | 16 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $265.52 | 6.9% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $254.79 | 6.6% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $210.40 | 5.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $196.58 | 5.1% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $191.10 | 5.0% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $190.75 | 5.0% | 10 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $131.88 | 3.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $121.97 | 3.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $115.29 | 3.0% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $112.72 | 2.9% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.11 | 2.7% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.25 | 2.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.12 | 1.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.93 | 1.6% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.90 | 1.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.65 | 1.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.23 | 1.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.75 | 1.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $27.43 | 0.7% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.04 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.45 | 0.7% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $23.79 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.74 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.03 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.66 | 0.4% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $14.57 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,836.54 | 186 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $465.19 | 21 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $454.20 | 24 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $329.66 | 16 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $265.52 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $249.14 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $217.22 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $191.10 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $191.10 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $176.34 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $158.72 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $146.10 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $115.29 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $113.95 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $112.72 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $103.11 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.39 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $98.55 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $84.25 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.03 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $80.42 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $80.42 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $71.12 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $67.55 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $67.55 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $67.55 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $61.26 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $61.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.71 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.71 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.55 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.90 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.65 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $41.23 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $41.23 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.75 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $32.03 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $27.43 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 150 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 62 |
| Furosemide | Furosemide | 157 | 50 |
| Gabapentin | Gabapentin | 153 | 36 |
| Omeprazole | Omeprazole | 153 | 42 |
| Eliquis | Apixaban | 150 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 50 |
| Sertraline Hcl | Sertraline Hcl | 134 | 37 |
| Losartan Potassium | Losartan Potassium | 132 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 45 |
| Lisinopril | Lisinopril | 107 | 40 |
| Potassium Chloride | Potassium Chloride | 104 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 15 |
| Prednisone | Prednisone | 89 | 70 |
| Meloxicam | Meloxicam | 75 | 16 |
| Montelukast Sodium | Montelukast Sodium | 72 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 20 |
| Lorazepam | Lorazepam | 60 | 17 |
| Trazodone Hcl | Trazodone Hcl | 59 | 24 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Metformin Hcl | Metformin Hcl | 57 | 15 |
| Tramadol Hcl | Tramadol Hcl | 55 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 20 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 15 |
| Simvastatin | Simvastatin | 50 | 15 |
| Azithromycin | Azithromycin | 48 | 43 |
| Carvedilol | Carvedilol | 48 | 17 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 18 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Allopurinol | Allopurinol | 34 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 24 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 21 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | 14 |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 13 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 14 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,836.54 · 186 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, CHARTIS CATHETER, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EOHILIA, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, LEQVIO, LINZESS, LOREEV XR, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PENMENVY, PREVNAR 20, PROCLAIM, PROLIA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYNDAMAX, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error